Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30080223 | 0.93 | CRBN (0.53) | CRBNDDB1IKZF3CCR2NAAA | |
| SCHEMBL26318088 | 0.93 | CRBN (0.53) | CRBNDDB1IKZF3CCR2NAAA | |
| SCHEMBL30080349 | 0.93 | CRBN (0.53) | CRBNDDB1IKZF3CCR2NAAA | |
| SCHEMBL26318101 | 0.93 | CRBN (0.53) | CRBNDDB1IKZF3CCR2NAAA | |
| SCHEMBL19370826 | 0.88 | CRBN (0.55) | CRBNDDB1IKZF3 | |
| SCHEMBL26318103 | 0.88 | CRBN (0.54) | CRBNDDB1IKZF3CCR2NAAA | |
| SCHEMBL20367601 | 0.87 | CRBN (0.49) | CRBNDDB1IKZF3CCR2NAAA | |
| Hydrochloric Acid SCHEMBL19359505 | 0.87 | CRBN (0.54) | CRBNDDB1IKZF3 | |
| SCHEMBL3770457 | 0.86 | CCR2 (0.62) | CRBNCCR2NAAA | |
| SCHEMBL3766769 | 0.86 | CCR2 (0.62) | CRBNCCR2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505560-B2 | Heterobifunctional compounds with improved specificity | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| EP-3676268-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITYFOR THE BROMODOMAIN OF BRD4 | Dana-Farber Cancer Institute, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019079701-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITYFOR THE BROMODOMAIN OF BRD4 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | MDM2, STUB1, UBE3C | CRBN 113/4885DDB1 249/4885IKZF3 685/4885 |
| US-11505560-B2 | Heterobifunctional compounds with improved specificity | MDM2, STUB1, UBE3C | CRBN 113/4885DDB1 249/4885IKZF3 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.